SCHEMBL3981987

SCHEMBL3981987

C=CCc1c(C#N)c2ccccc2oc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VKORC1 Q9BQB6 3/20 0.45
ALDH1A1 P00352 6/20 0.44
NQO1 P15559 3/20 0.44
LMNA P02545 3/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 2/20 0.44
MAPK1 P28482 2/20 0.44
ABCB11 O95342 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDE4D Q08499 1/20 0.44
PCSK7 Q16549 1/20 0.44
GPR35 Q9HC97 1/20 0.44
KDM4E B2RXH2 4/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143392 0.78 VKORC1 (0.71) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL3988877 0.78 GAA (0.57) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL5478821 0.78 VKORC1 (0.51) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL15842754 0.76 KDM4E (0.54) ALDH1A1NQO1LMNAMEN1CYP1A2
SCHEMBL7192591 0.75 GAA (0.57) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL7140693 0.74 CA12 (0.52) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL4353785 0.72 VKORC1 (0.43) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL10687334 0.72 KDM4E (0.53) VKORC1ALDH1A1NQO1LMNAMEN1
SCHEMBL29206918 0.72 KDM4E (0.57) ALDH1A1MEN1CYP1A2CYP3A4KMT2A
SCHEMBL27152753 0.71 ESR1 (0.46) VKORC1ALDH1A1NQO1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667988-B1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMA INC (US) 2013-04-10 EP disclosed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 US disclosed
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 EP disclosed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 WO disclosed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054681-A1 Coumarins as iNOS inhibitors NOS2, NOS1, NOS3 VKORC1 90/4885ALDH1A1 169/4885NQO1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.